Axsome Therapeutics (AXSM): Valuation Check After Strong Revenue Growth from Auvelity, Sunosi and Symbravo

Axsome Therapeutics (AXSM) just followed up a 63% year over year revenue jump with plans to showcase its growth story at the Piper Sandler Healthcare Conference, putting Auvelity, Sunosi and new migraine drug Symbravo firmly in the spotlight.

See our latest analysis for Axsome Therapeutics.

That growth narrative is increasingly reflected in the market, with Axsome’s share price at $147.81 and a roughly 69% year to date share price return pointing to building momentum. The three year total shareholder return near 89% underlines how sustained the rerating has been.

If Axsome’s run has you thinking about what else could surprise to the upside in healthcare, it might be worth scanning healthcare stocks for the next set of contenders.

With revenue surging but profits still negative and the stock already up sharply in 2025, is Axsome still trading below its true potential, or are markets already pricing in the next leg of its growth story?

Most Popular Narrative: 18.6% Undervalued

Axsome Therapeutics' most followed narrative sees fair value comfortably above the recent 147.81 share price, framing the current rally as only part of the story.

The analysts have a consensus price target of $176.841 for Axsome Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $200.0, and the most bearish reporting a price target of just $144.0.

Read the complete narrative.

Want to see what is powering this bold upside view? The narrative leans on rapid revenue expansion, a sharp swing into profitability, and a future earnings multiple more often reserved for sector standouts. Curious how those ingredients combine into that fair value call? The full narrative breaks down the projections line by line.

Result: Fair Value of $181.58 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that upside case faces real world friction if SYMBRAVO adoption lags, or if payer pushback keeps gross to net discounts stubbornly high.

Find out about the key risks to this Axsome Therapeutics narrative.

Build Your Own Axsome Therapeutics Narrative

If you are not convinced by this view, or prefer to dig into the numbers yourself, you can build a custom Axsome thesis in minutes: Do it your way.

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Axsome Therapeutics.

Ready for more investing opportunities?

Before the market moves on without you, tap into fresh ideas beyond Axsome using Simply Wall St screeners tailored to different strategies and risk profiles.

• Capture mispriced potential by targeting companies trading below intrinsic value, starting with these 915 undervalued stocks based on cash flows that could reset higher as sentiment shifts.
• Ride structural growth by focusing on innovators at the intersection of medicine and algorithms, using these 30 healthcare AI stocks to pinpoint tomorrow's category leaders.
• Boost your income stream by securing robust payouts and stability, and by zeroing in on these 14 dividend stocks with yields > 3% that can support returns even when markets turn choppy.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com